Letters to the Editor
- John A Crowhurst, Peter Bird
- Aust Prescr 2009;32:60
- 1 June 2009
- DOI: 10.18773/austprescr.2009.030
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, – I am appalled to find that there are now two 'over-the-counter' S3 medications bearing the Sudafed label which do not contain pseudoephedrine. The first is Sudafed PE tablets, the second Sudafed nasal spray.
The new products contain phenylephrine, which is an active vasoconstrictor and decongestant when administered intravenously or intranasally, but its efficacy in a per-oral tablet formulation is questionable, as most pharmacological data suggest its first-pass metabolism is almost complete.
My family's experience in using these tablets confirms this. Indeed, I was so appalled that I returned the Sudafed PE tablets to the pharmacy where purchased, pointing out that they were not as labelled.
Sudafed has been a registered, recognised name for pseudoephedrine for more than 40 years, so to have it used for a completely different compound is confusing and misleading. How can the Therapeutic Goods Administration justify allowing the misuse of this name? What data were submitted to justify using the Sudafed label on products which do not contain Sudafed?
John A Crowhurst
Senior Consultant Anaesthetist
Mercy Hospital for Women
Dr Peter Bird, Head, Office of Non-prescription Medicines, Therapeutic Goods Administration, comments:
In recent years, concerns about the diversion of pseudoephedrine to the illicit drug trade led to more stringent limitations being placed on the supply of medications containing this ingredient. These restrictions resulted in some companies formulating new products that replaced pseudoephedrine with phenylephrine hydrochloride.
In common with general retail practice, over-the-counter (OTC) medicine companies use brand extensions (umbrella/ family branding) to market their products. The Therapeutic Goods Administration (TGA ) has specific guidelines to determine the acceptability of proposed brand extensions for OTC medicines (see http://tga.gov.au/docs/pdf/argom_5.pdf).
While the safety and efficacy of phenylephrine has been documented in standard reference texts, it is recognised that there may be differences in effectiveness compared to pseudoephedrine. For this reason, where there are medicines containing either pseudoephedrine or phenylephrine with similar presentations, the TGA requires that the letters 'PE', together with other distinguishing features, are included prominently on the label of the product containing phenylephrine. This is consistent with practices in a number of other countries in which these medicines are marketed. Similarly, nasal sprays containing decongestant ingredients are required to include distinguishing features on their labels.
Senior Consultant Anaesthetist, Mercy Hospital for Women Heidelberg, Vic.
Head, Office of Non-prescription Medicines, Therapeutic Goods Administration